Type 1 Diabetes TrialNet Clinical Network Hub

描述（由申请人提供）：Diabetes TrialNet是一个国际临床试验网络，旨在延迟或预防1型糖尿病的发作。如上所述，新的糖尿病TrialNet结构现在将包括糖尿病TrialNet临床中心，其主任将是 TrialNet领导团队的一部分，包括NIH、TrialNet协调中心和TrialNet主席的代表。Benaroya研究所（BRI）是T1 D研究的纽带，在T1 D预测和预防方面拥有数十年的临床试验经验，Greenbaum博士是唯一有资格担任TrialNet临床网络中心（HUB）的人。本申请描述了我们成为糖尿病TrialNet临床中心的建议。我们专注于三个领域;这些活动旨在：（a）加强风险筛查和预防试验招募;（B）支持临床试验;（c）加强临床管理，包括拟议的试点研究，以测试增加招募、保留和成本效益的创新想法。

DESCRIPTION (provided by applicant): Diabetes TrialNet is an international clinical trial network aimed to delay or prevent the onset of type 1 diabetes. As described, the new Diabetes TrialNet structure will now include a Diabetes TrialNet Clinical Hub, the Director of which will be part of the TrialNet leadership team including representatives of the NIH, the TrialNet Coordinating Center, and TrialNet chairman. The Benaroya Research Institute (BRI) serves as a nexus of T1D research, and with decades of clinical trial experience in T1D prediction and prevention, Dr. Greenbaum is uniquely qualified to serve as the TrialNet Clinical Network Hub (HUB). This application describes our proposal to become the Diabetes TrialNet Clinical HUB. We focus on three areas; activities to (a) enhance risk screening and prevention trial recruitment, (b) support clinical trials, and (c) enhance clinical administration and include proposed pilot studies to test innovative ideas for increasing recruitment, retention, and cost efficiencies.